Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis

Current Eye Research

Volumn 30, Issue 2, 2005, Pages 93-101

  Ishikawa, Tomoaki ^a   Hokama, Hideyuki ^a   Katagiri, Yoshiaki ^a   Goto, Hiroshi ^a   Usui, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Experimental uveitis; Immunosuppression; Intravitreal injection; Neuroprotection; Tacrolimus

Indexed keywords

BALANCED SALT SOLUTION; BETAMETHASONE; BOVINE SERUM ALBUMIN; CALCINEURIN; IMMUNOPHILIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD EYE BARRIER; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE BLOOD FLOW; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; UVEITIS;

ANIMALS; BETAMETHASONE; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; MALE; NEUROPROTECTIVE AGENTS; RABBITS; SERUM ALBUMIN, BOVINE; TACROLIMUS; UVEITIS; VITREOUS BODY;

EID: 17144425765     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490904368     Document Type: Article

References (31)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK-506, A novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249-1255.
2. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987;139:1797-1803.
3. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2(8670):1000-1004.
4. Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci. 1988;29:1265-1271.
5. Mochizuki M, Ikeda E, Shirao M, Fujito S, Yoshimura K, Shimada N. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res. 1992;11(Suppl):87-95.
6. Mochizuki M, Masuda K, Sakane T, Inaba G, Ito K, Kogure M, Sugino N, Usui M, Mizushima Y, Ohno S, Miyanaga Y, Hayasaka S, Ohizumi K. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc. 1991;23:3343-3346.
7. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723-728.
8. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003;135:297-302.
9. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 1994;371:336-339.
10. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A. 1993;90:9808-9812.
11. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda Y. Tacrolimus(FK506) attenuates leukocyte accumulation after transient retinalischemia. Stroke. 1998;29:1431-1438.
12. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343.
13. Uchino H, Minamikawa-Tachino R, Kristian T, Perkins G, Narazaki M, Siesjo BK, Shibasaki F. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis. 2002;10:219-233.
14. Furuichi Y, Katsuta K, Maeda M, Ueyama N, Moriguchi A, Matsuoka N, Goto T, Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: Dose dependency, therapeutic time window and long-term efficacy. Brain Res. 2003;965:137-145.
15. Freeman EE, Grosskreutz CL. The effects of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci. 2000;41:1111-1115.
16. Kikuchi M, Kashii S, Mandai M, Yasuyoshi H, Honda Y, Kaneda K, Akaike A. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1998;39:1227-1232.
17. Lightman S, Chan CC. Immune mechanisms in choroido-retinal inflammation in man. Eye. 1990;4:345-353.
18. Hikita N, Chan CC, Whitcup SM, Nussenblatt RB, Mochizuki M. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Curr Eye Res. 1995;14:209-214.
19. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.
20. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001;29:2-6.
21. Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, Kaizu T, Tanaka H, Niwa M. A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc. 1987;19(5 Suppl 6):23-29.
22. Hall JM, O'Connor GR. Correlation between ocular inflammation and antibody production. I. Serum antibody response following intravitreal immunization with protein antigens. J Immunol. 1970;104:432-439.
23. Hogan MJ, Kimura SM, Thygeson P. Signs and symptoms of uveitis. I. AnteriorUveitis. Am J Ophthalmol. 1959;47:171-180.
24. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56.
25. Caspi RR, Chan CC, Fujino Y, Najafian F, Grover S, Hansen CT, Wilder RL. Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis. J Neuroimmunol. 1993;47:177-188.
26. Sartani G, Silver PB, Strassmann G, Chan CC, Caspi RR. Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents. Curr Eye Res. 1995;14:887-896.
27. Hughes WF. Quantitation of ischemic damage in the rat retina. Exp Eye Res. 1991;53:573-582.
28. Passos E, Genaidy MM, Peyman GA. Ocular toxicity of intravitreal tacrolimus. Ophthalmic Surg Lasers. 2002;33:140-144.
29. Conde M, Andrade J, Bedoya FJ, Santa Maria C, Sobrino F. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology. 1995;84:476-481.
30. Kaplan HJ, Diamond JG, Brown SA. Vitrectomy in experimental uveitis. I. Operative technique in rabbits. Arch Ophthalmol. 1979;97:331-335.
31. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scieral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci. 2003;44:4845-4852.